Loading stock data…
SKYE
$0.82-0.06 (-6.29%)
After Hours$0.84+0.01 (+1.74%)· Last close May 1
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Skye Bioscience, Inc. in the Healthcare sector is trading at $0.82. The stock is currently near its 52-week low of $0.57, remaining 54.0% below its 200-day moving average. Technical signals show neutral RSI of 57 and bullish MACD crossover, explaining why SKYE maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 57) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.82
Potential Upside
5%
Whystock Fair Value$0.86
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripher...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.89M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-60.44%
Volume
Today's trading volume
317,646
Recent News
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
Halozyme Therapeutics (NASDAQ:HALO) executives highlighted the company’s royalty-driven growth outlook and expanding subcutaneous drug delivery platform during remarks at the Citizens Life Sciences Conference, pointing to strong momentum from key partnered products, new collaboration activity, and r
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...
Skye Bioscience Inc (SKYE) reports promising weight loss results and strategic R&D collaborations, despite challenges in dosing and delivery.
Companies Like Skye Bioscience (NASDAQ:SKYE) Could Be Quite Risky
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience
Halozyme Therapeutics (HALO) shares are in focus after the company entered a non exclusive global collaboration with Skye Bioscience in December 2025 to apply its ENHANZE drug delivery technology to a potential obesity treatment. See our latest analysis for Halozyme Therapeutics. The Skye Bioscience agreement lands at a time when Halozyme’s share price has picked up momentum, with a 15.47% 1 month share price return and 12.16% 3 month share price return. The 1 year total shareholder return of...
Skye Bioscience Inc (SKYE) Q3 2025 Earnings Call Highlights: Promising Study Results and ...
Skye Bioscience Inc (SKYE) reports encouraging phase 2A study outcomes but faces increased R&D expenses and net loss.